Bevacizumab, a monoclonal antibody directed against VEGF, showed a promising activity in combination with platinum-etoposide as the first-line treatment of patients with ES-SCLC, and two randomized studies confirmed that bevacizumab improved PFS, but failed to prolong OS (13, 14). This evidence concerns the gene VEGFA and small cell lung carcinoma.